-
1 Comment
Onconova Therapeutics, Inc is currently in a long term downtrend where the price is trading 35.8% below its 200 day moving average.
From a valuation standpoint, the stock is 46.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 714.9.
Onconova Therapeutics, Inc's total revenue rose by 90.0% to $57K since the same quarter in the previous year.
Its net income has increased by 99.9% to $-6K since the same quarter in the previous year.
Finally, its free cash flow fell by 2.3% to $-5M since the same quarter in the previous year.
Based on the above factors, Onconova Therapeutics, Inc gets an overall score of 3/5.
Under normal circumstances, the fund will invest at least 80% of the value of its net assets, plus any borrowings for investment purposes, in financial instruments (for example, swaps and futures) that, in the aggregate, provide leveraged exposure to the Underlying Security equal to approximately two times its daily performance. It is non-diversified.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for ONTX using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2026